Global Facial Injectable Market is valued at USD 14.25 Billion in 2020 and is expected to reach USD 25.82 Billion by 2027 with a CAGR of 8.86% over the forecast period.
Global Facial Injectable Market: Global Size, Trends, Competitive, Historical &Forecast Analysis, 2021-2027- Increasing demand to enhance the aesthetic beauty and rising preference for minimally invasive procedures are some of the major factors driving the growth of the Global Facial Injectable Market.
Facial injectables are the non-surgical treatments used to correct signs of aging. These products are used in facial surgeries and facial rejuvenation. Products of Facial injectables are majorly used for the reduction the signs of aging and increase aesthetic beauty. Also its treatments are extremely helpful for removing wrinkles, smoothing away age lines, restoring facial volume and even reducing chin fat to take care of a double chin. These are injected underneath the facial skin surface. Some normally used facial injectable contain hyaluronic acid, botulinum toxin A type, and polymer fillers. One of the popular types of facial injectables is the dermal filler; these dermal fillers are mostly known for smoothing facial wrinkles that come about as a result of the aging process and environmental factors. Some filler can also restore facial volume and plump the lips.
Covid-19 has also impacted the growth of the global facial injectable market as due to Covid-19 governments worldwide are responding to all the essential measures, such as social distancing, large-scale quarantines and travel restrictions that are anticipated to impact the businesses and consumer spending negatively. Also the pandemic has resulted in decreased public mobility and also impacted the therapeutic & surgical industry significantly as the surgical procedures and screening programs which are non-immediate and are being postponed to reduce the load on healthcare infrastructure.
Global facial injectable market is segmented product type, application and region & country level. On the basis of type, the global facial injectable market is segmented into hyaluronic acid, collagen, botulinum toxin, polymers and particles. On the basis of application, the global facial injectable market is segmented into hospitals, clinics, research and others.
The key players of Global Facial Injectable Market are such as
On June 29th, 2021; Galderma declared the FDA endorsement of Restylane Contour for cheek expansion and amendment of midface contour lacks in grown-ups 21 years or older. The new hyaluronic acid (HA) filler is Galderma's just item in the United States planned with XpresHAn Technology for the cheek.
As the facial injectables are used in the therapeutic procedures for volumizing lips & cheeks and reduce wrinkles by injecting directly into them as it relaxes the muscles that create wrinkles. Also as wrinkles are one of the signs of ageing, and many of the early age patients and male patients population are opting for aesthetic procedures like lip augmentation, face lift, acne treatment, scars treatment and aesthetic procedures. These are the most common type of facial aesthetic procedures require facial injectable. Thus, the growing elderly population and increasing demand to enhance the aesthetic beauty are leading the increased adoption of facial injectable.
In addition, the increasing shift towards the minimally invasive procedures are also supplementing the market growth. For instance; according to the American Society of Plastic Surgeons (ASPS), in U.S. about 17.7 million minimally invasive and surgical cosmetic products were performed in 2018 in which nearly about 15.9 million products were minimally invasive. Thus, the increasing adoption of minimally invasive surgeries, which are combined with the availability of a wide range of such facial injectables treatment options, are also driving the market for facial injectables.
However, the side effects of undertaking the cosmetic surgeries or various facial surgeries which also involve the usage of facial injectables may hamper the growth of the market. In spite of that, the rising interest in physical appearance along with an increase in disposable income among the middle-class population in developing countries may create more opportunities for the further growth of the market.
North America region is expected to dominate the global facial injectable market due to the rising geriatric population, increasing awareness about aesthetic surgical procedures, technological developments in cosmetic procedures and presence of key market players in this region. For instance; as there are number of key players present in the United States, so there is competition between them to launch the new products in the market which drive the country in the global market. In January 2020, Revance Therapeutics announced transformative aesthetics collection transaction with exclusive U.S. division contract of FDA-Approved dermal fillers from Teoxane SA. TEOXANE SA RHA item is the underlying and simply scope of FDA- approved dermal fillers for adjustment of dynamic wrinkles.
Also Asia Pacific is expected to witness fastest growth in the global facial injectables market due to the growing focus towards the physical appearance in the developing countries such as India, China, Australia, and South Korea.
The regions covered in Global Facial Injectable Market report are North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. On the basis of country level, the market of Global Facial Injectable Market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
• Rest of Europe
• South Korea
• Rest Of APAC
• Rest of South America
Middle East and Africa
• Saudi Arabia
• South Africa
• Rest Of MEA
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 14.25 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 25.82 Billion|
|Tables, Charts & Figures:||175|
|Poppy Seeds Manufacturers||Bloomega BioTechnology, Allergan, Merz Pharma, Bausch Health, Galderma, Integra Lifesciences, Tei Biosciences, Fibrogen, and Others|
|Segments Covered||By Product Types, By Application|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|